DT
HealthMore in Health→
CAR T’s biggest weak point may be the patient’s own aging immune cells
Key Takeaways
- Rutgers researchers linked CAR T underperformance to senescent CD8+ T cells used as starting material.
- Higher senescence burdens reduced cell expansion under standard CAR T culture conditions.
- Analysis of published lymphoma data found stronger senescence signatures were associated with higher failure risk.
- The work suggests pre-manufacturing cell-quality screening could improve patient selection and product design.
DE
DT Editorial Team··via medicalxpress.com